Modification of malignancy by 5-bromodeoxyuridine. Studies of reversibility and immunological effects.
D000305:Adrenal Cortex Hormones; D000310:Adrenal Gland Neoplasms / Q000378:metabolism; D000818:Animals; D001973:Bromodeoxyuridine / Q000494:pharmacology*; D002460:Cell Line; D002999:Clone Cells; D003561:Cytarabine / Q000494:pharmacology; D004247:DNA / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D006822:Hybrid Cells; D008545:Melanoma / Q000276:immunology / Q000378:metabolism; D008722:Methods; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000378:metabolism*; D009447:Neuroblastoma / Q000378:metabolism; D010860:Pigments, Biological / Q000378:metabolism; D013997:Time Factors
D000305:Adrenal Cortex Hormones; D010860:Pigments, Biological; D003561:Cytarabine; D004247:DNA; D001973:Bromodeoxyuridine